The in vitro antibacterial potencies of A-56619 and A-56620, two new aryl-fluoroquinolones, were compared with the potency of norfloxacin against a broad spectrum of organisms. Cefotaxime, aztreonam, piperacillin, imipenem, penicillin, and gentamicin were also tested for reference purposes. The MICs required to inhibit at least 90% of the strains tested ranged from 0.25 to 4 p,g/ml for A-56619 and from 0.06 to 0.5 ,ug/ml for A-56620 for members of the Enterobacteraceae. A-56619 was generally twofold less potent and A-56620 was twofold more potent than norfloxacin against most aerobic gram-negative bacilli, including members of the Enterobacteriaceae and Pseudomonas aeruginosa. Against indole-positive Proteus, MorganeUa, Providencia rettgeri, and Serratia strains, A-56619 was at least 8-to 16-fold less potent than norfloxacin. A-56619 and A-56620 were four-to eightfold more potent than norfloxacin against Staphylococcus aureus and equally potent to fourfold more potent against Streptococcus species, Haemophilus influenzae, and Neisseria gonorrhoeae. The MICs of A-56619 aq4 A-56620 were only slightly affected by increased inoculum size or by the addition of various cations at physiologic concentrations. A-56619 was three-to fivefold less active at pH 8.0 than at pH 6.5 or 7.2. A-56620 was twofold less active at pH 6.5 than at pH 8.0 or 7.2 against members of the Enterobacteriaceae and Pseydmonas aeruginosa; similar pH variations did not affect A-56620 activity against gram-positive cocci. The potencies of A-56619, A-56620, and norfloxacin were less in urine than in Mueller-Hinton broth; however, this effect was more pronounced with norfloxacin. Human serum at a concentration of 50% caused a 4-to 64-fold decrease in the potency of A-56619 and an average 4-fold decrease in the potency of A-56620, compared with no efect on the potency of norfioxacin. A-56619, A-56620, and norfloxacin were bactericidal and, at four times the MIC, reduced the viable cell counts of Escherichia coli, Staphyloeoccus aureus, and Pseudomonas aeruginosa by approximately 99.9% within 2 h. A-56619, A-56620, and norfloxacin showed no significant synergistic activity and no gntagonism when they were combined with aminoglycoside or j-lactam antimicrobial agents.
The group of antimicrobial agents termed the 4-quinolones is currently the subject of much interest and research. These agents are congeners of nalidixic acid, which was introduced into clinical use in 196J. Nalidixic acid is still useful for treatment of urinary tract infections but is active mainly against gram-negative bacteria. Addition of a 7-piperazinyl group and a 6-fluorine to the nalidixic acid molecule has resulted in a number of compounds with potent broadspectrum antibacterial activity, including activity against Pseudomonas aeruginosa. Included in this group of recently described agents are amifloxacin (15) , ciprofloxacin (2, 4, 54 16, 20, 21) , enoxacin' (3), norfloxacin (9, 10, 11, 13, 14) , ofloxacin (7, 17) , and pefloxacin (8) .
A-56619 and A-56620 are two new aryl-fluoroquinolone antimicrobial ageits which are structurally similar to norfloxacin except for a p-fluorophenyl substituent at position 1. A-56619 also has a methyl group in the piperazine ring. The chemical structures of A-56619, 1-p-fluorophenyl-6-fluoro-1,4-dihydro-4 oxo-7-(4-methyl-1-piperazinyl)-quinolone-3-carboxylic acid hydrochloride, and A-56620, 1-p-fluorophenyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinolone-3-carboxylic acid hydrochloride, are shown in Fig. 1 .
In this paper we describe the in vitro potencies and properties of A-56619 and A-56620 compared with the potencies and properties of norfloxacin and various reference antimicrobial agents. (Some of the results have been pre- dard agar dilution method (19) Continued on following page (Table 3) . The MICs of A-56619 and was similar to norfloxacin activity against Streptococcus A-56620 ranged from 8-to 128-fold higher (mean, 33-fold) species, including enterococci; however, A-56620 was genand from 32-to 256-fold higher (mean, 140-fold), respecerally twofold more active against Streptococcus species.
tively, in urine against members of the Enterobacteriaceae; The MBCs of A-56619 and A-56620 for 37 aerobic gramthe MICs were 4-to 8-fold higher and 32-to 64-fold higher, negative and 13 gram-positive organisms were generally respectively, against Pseudomonas aeruginosa, and 2-to equal to or twofold greater than the MICs (data not shown).
16-fold higher, respectively, against staphylococci and strepThe mean log2 ratio of MBC to MIC was calculated for each tococci. Norfloxacin was 64-to 1,024-fold less active (mean, species tested. This ratio for A-56619, A-56620, and norflox-375-fold) in urine against members of the Enterobacteriaacin was less than 2.0 for all species, and for most species it ceae, 32-to 128-fold less active against Pseudomonas aeruwas less than 1.5. When the inoculum size used for MIC ginosa, and 32-fold less active against gram-positive cocci. tests was increased from 105 to 107 CFU/ml, there was a twoThe effects of 50% inactivated human serum on the to fourfold maximum increase in the MIC of A-56619, potencies of A-56619, A-56620, and norfloxacin are shown in A-56620, or norfloxacin against each of the 50 organisms. Table 4 . The potencies of A-56619 and A-56620 were deThe effects of pH on A-56619, A-56620, and norfloxacin creased 4-to 64-fold and 1-to 16-fold, respectively, by 50% activities against 37 gram-negative and 13 gram-positive serum. Serum had little or no effect on the potency of bacteria are shown in Table 2 . Generally, the MICs of norfloxacin. The cations Fe2 , Ca2+, Mg2+, Na+, and K+ A-56619 were fourfold higher at pH 8.0 and similar at pH 6.5
were added to Mueller-Hinton broth to determine their compared with the MICs at pH 7.2 against gram-negative effects on the potencies of A-56619, A-56620, and norfloxbacilli, including members of the Enterobacteriaceae and acin against strains of E. coli, Staphylococcus aureus, and Pseudomonas, and gram-positive cocci. The MICs of Pseudomonas aeruginosa. Magnesium at four times the , and cefotaxime (x) against E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa. A control (0) was also included. Each agent was added to a logarithmic-phase culture at zero time at four times the MIC. The MICs of A-56619 against E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa were 0.06, 0.25, and 2 ,ug/ml, respectively; the MICs of norfloxacin against E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa were 0.03, 1, and 1 ,ug/ml, respectively; the MICs of gentamicin against E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa were 0.25, 0.12, and 4 1Lg/ml, respectively; and the MICs of cefotaxime against E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa were 0.06, 2, and 16 ,ug/ml, respectively. caused a 16-fold decrease in the potency of A-56619 against Escherichia coli, and iron at four times the normal serum concentration caused a 16-fold decrease in the potency of norfloxacin against Escherichia coli. Other cations and concentrations had no significant effect (seightfold difference) on A-56619, A-56620, or norfloxacin potency (data not shown).
The activities of A-56619, A-56620, and norfloxacin against six organisms were generally not changed when these compounds were combined with cefoxitin, cefotaxime, ampicillin, gentamicin, or amikacin (data not shown). No antagonism was observed with any combination. Several combinations containing A-56619, A-56620, or norfloxacin were synergistic, but none had a fractional inhibitory index of less than 0.38. In addition, the synergism that occurred was random, and no clear pattern of synergism with one species was observed. Thus, significant synergism was not observed with any combination.
The extent and rapidity of killing by A-56619, A-56620, norfloxacin, gentamicin, and cefotaxime were determined by adding each antimicrobial agent to logarithmic-phase cultures of Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. The viable counts determined 30 min to 24 h after addition of four times the MIC of each drug are shown in Fig. 2 A-56619 and A-56620 are two new aryl-fluoroquinolone antimicrobial agents with potencies and broad-spectrum activities similar to the potencies and activities of other compounds belonging to this class. The overall potencies of A-56619 and A-56620 against most organisms in this study were of the same order of magnitude as the potencies of norfloxacin, gentamicin, cefotaxime, imipenem, and aztreonam. Ciprofloxacin has been reported to be approximately four-to eightfold more potent than norfloxacin against most organisms (2, 4, 20 CFU/ml. Similar results have been observed with norfloxacin and ciprofloxacin (9-11, 13, 16, 20) . A-56619 and A-56620 are similar to other quinolones (3, 7, 8, (15) (16) (17) 20) in being rapidly bactericidal against logarithmic growth phase organisms.
A-56619 is more potent at pH 7.2 and 6.5 than at pH 8.0, in contrast to norfloxacin. A-56620 is more potent against gram-negative bacteria at pH 8.0 and 7.2 than at pH 6.5, which is similar to the potency of norfloxacin. The potency of ciprofloxacin has been reported to be decreased at acid pH values (5) . Norfloxacin and ciprofloxacin have also been reported to be less active in urine agar (4, 5, 9, 16) . In this study, the activities of A-56619, A-56620, and norfloxacin were less in urine than in broth, but A-56619 activity was affected to a substantially lesser degree. Since many infection sites, such as abscesses, are acidic, the activity of A-56619 may be greater in vivo than expected based simply on MICs. The activity of A-56619 was decreased more by human serum than the activity of A-56620 or porfloxacin. It is possible that A-56619 is bound significantly to protein or other serum components. This is now under investigation. It is also possible that pH changes caused by the addition of serum to growth medium could have resulted in inactivation of A-56619. Serum has little or no effect on the activity of ciprofloxacin (4, 16) .
Based on results of this study, clinically significant synergy or antagonism would not be expected against bacteria from a combination of A-56619 pr A-56620 and commonly used aminoglycosides or P-lactams. The development of resistance to A-56619 and A-56620 was not evaluated in this study. Development of resistance to A-56619 and A-56620 will be evaluated in future studies.
The potent broad-spectrum activities and other characteristics of A-56619 and A-58620 make these compounds potentially useful therapeutic agents. 
